Complement analysis in the 21st century

Molecular Immunology

Volumn 44, Issue 16, 2007, Pages 3838-3849

  Mollnes, Tom Eirik ^a,b   Jokiranta, T Sakari ^c   Truedsson, Lennart ^d   Nilsson, Bo ^e   Rodriguez de Cordoba, Santiago ^f   Kirschfink, Michael ^g  

^a UNIVERSITY OF OSLO   (Norway)

^b NORDLAND HOSPITAL   (Norway)

^c UNIVERSITY OF HELSINKI   (Finland)

^d Institute of Laboratory Medicine   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Complement assay; Genetic analyses; Neoepitope; Proteomic analyses

Indexed keywords

LECTIN;

ANTIPHOSPHOLIPID SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; IMMUNOCHEMISTRY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PROTEOMICS; REVIEW;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC TECHNIQUES;

EID: 34548321363     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.06.150     Document Type: Review

References (114)

1. Arumugam T.V., Shiels I.A., Woodruff T.M., Granger D.N., and Taylor S.M. The role of the complement system in ishemia-reperfusion injury. Shock 21 (2004) 401-409
2. Atkinson J.P., and Frank M.M. Bypassing complement: evolutionary lessons and future implications. J. Clin. Invest. 116 (2006) 1215-1218
3. Bergh K., and Iversen O.J. Measurement of complement activation in rabbit plasma or serum using monoclonal antibodies against C5a. Scand. J. Immunol. 29 (1989) 333-341
4. Bevers E.M., Zwaal R.F., and Willems G.M. The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin. Clin. Immunol. 112 (2004) 150-160
5. Black M.M., Bhogal B.S., and Willsteed E. Immunopathological techniques in the diagnosis of bullous disorders. Acta Derm. Venereol. Suppl. (Stockh) 151 (1989) 96-105
6. Borrebaeck C.A. Antibody microarray-based oncoproteomics. Expert Opin. Biol. Ther. 6 (2006) 833-838
7. Bouwman L.H., Roep B.O., and Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Human Immunol. 67 (2006) 247-256
8. Brodsky R.A., and Hu R. PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis. Leuk. Lymphoma 47 (2006) 1215-1221
9. Caprioli J., Bettinaglio P., Zipfel P.F., Amadei B., Daina E., Gamba S., Skerka C., Marziliano N., Remuzzi G., and Noris M. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J. Am. Soc. Nephrol. 12 (2001) 297-307
10. Caprioli J., Castelletti F., Bucchioni S., Bettinaglio P., Bresin E., Pianetti G., Gamba S., Brioschi S., Daina E., Remuzzi G., and Noris M. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum. Mol. Genet. 12 (2003) 3385-3395
11. Couser W.G. Pathogenesis of glomerulonephritis. Kidney Int. 44 (1993) S19-S26
12. Crowson A.N., Mihm Jr. M.C., and Magro C.M. Cutaneous vasculitis: a review. J. Cutan. Pathol. 30 (2003) 161-173
13. Davis M.D., and Brewer J.D. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol. Allergy Clin. North Am. 24 (2004) 183-213 vi
14. Deppisch R., Schmitt V., Bommer J., Hansch G.M., Ritz E., and Rauterberg E.W. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int. 37 (1990) 696-706
15. Dragon-Durey M.A., Loirat C., Cloarec S., Macher M.A., Blouin J., Nivet H., Weiss L., Fridman W.H., and Fremeaux-Bacchi V. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16 (2005) 555-563
16. Edwards A.O., Ritter III R., Abel K.J., Manning A., Panhuysen C., and Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 308 (2005) 421-424
17. Ekdahl K.N., Norberg D., Bengtsson A.A., Sturfelt G., Nilsson U.R., and Nilsson B. A rapid, inexpensive, and easy-to-perform hemolytic complement assay using serum or buffer-changed EDTA-Plasma: its use for differential diagnosis and follow-up of patients with systemic lupus erythematosus. Clin. Vaccine Immunol. 14 (2007) 549-555
18. Esparza-Gordillo J., Goicoechea de Jorge .E., Buil A., Carreras B.L., Lopez-Trascasa M., Sanchez-Corral P., and Rodriguez de Cordoba S. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 14 (2005) 703-712
19. Esparza-Gordillo J., Goicoechea de Jorge .E., Garrido C.A., Carreras L., Lopez-Trascasa M., Sanchez-Corral P., and Rodriguez de Cordoba S. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol. Immunol. 43 (2006) 1769-1775
20. Figueroa J.E., and Densen P. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4 (1991) 359-395
21. Fredrikson G.N., Truedsson L., and Sjoholm A.G. New procedure for the detection of complement deficiency by ELISA-analysis of activation pathways and circumvention of rheumatoid factor influence. J. Immunol. Methods 166 (1993) 263-270
22. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., Vigneau C., Kuypers D., Boudailliez B., Loirat C., Rondeau E., and Fridman W.H. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 41 (2004) E84
23. Fremeaux-Bacchi V., Kemp E.J., Goodship J.A., Dragon-Durey M.A., Strain L., Loirat C., Deng H.W., and Goodship T.H. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J. Med. Genet. 42 (2005) 852-856
24. Fung M., Loubser P.G., Undar A., Mueller M., Sun C., Sun W.N., Vaughn W.K., and Fraser Jr. C.D. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J. Thorac. Cardiovasc. Surg. 122 (2001) 113-122
25. Fure H., Nielsen E.W., Hack C.E., and Mollnes T.E. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand. J. Immunol. 46 (1997) 553-557
26. Garratty G. The significance of complement in immunohematology. Crit. Rev. Clin. Lab. Sci. 20 (1984) 25-56
27. Garred P., Larsen F., Seyfarth J., Fujita R., and Madsen H.O. Mannose-binding lectin and its genetic variants. Genes Immun. 7 (2006) 85-94
28. Gertz M.A. Cold agglutinin disease and cryoglobulinemia. Clin. Lymphoma 5 (2005) 290-293
29. Goicoechea de Jorge E., Harris C.L., Esparza-Gordillo J., Carreras L., Arranz E.A., Garrido C.A., Lopez-Trascasa M., Sanchez-Corral P., Morgan B.P., and Rodriguez de Cordoba S. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 240-245
30. Gold B., Merriam J.E., Zernant J., Hancox L.S., Taiber A.J., Gehrs K., Cramer K., Neel J., Bergeron J., Barile G.R., Smith R.T., Hageman G.S., Dean M., Allikmets R., Chang S., Yannuzzi L.A., Merriam J.C., Barbazetto I., Lerner L.E., Russell S., Hoballah J., Hageman J., and Stockman H. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 38 (2006) 458-462
31. Hageman G.S., Anderson D.H., Johnson L.V., Hancox L.S., Taiber A.J., Hardisty L.I., Hageman J.L., Stockman H.A., Borchardt J.D., Gehrs K.M., Smith R.J., Silvestri G., Russell S.R., Klaver C.C., Barbazetto I., Chang S., Yannuzzi L.A., Barile G.R., Merriam J.C., Smith R.T., Olsh A.K., Bergeron J., Zernant J., Merriam J.E., Gold B., Dean M., and Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 7227-7232
32. Haines J.L., Hauser M.A., Schmidt S., Scott W.K., Olson L.M., Gallins P., Spencer K.L., Kwan S.Y., Noureddine M., Gilbert J.R., Schnetz-Boutaud N., Agarwal A., Postel E.A., and Pericak-Vance M.A. Complement factor H variant increases the risk of age-related macular degeneration. Science 308 (2005) 419-421
33. Hartmann H., Lubbers B., Casaretto M., Bautsch W., Klos A., and Kohl J. Rapid quantification of C3A and C5A using a combination of chromatographic and immunoassay procedures. J. Immunol. Methods 166 (1993) 35-44
34. Hawlisch H., Vilsendorf M.A.Z., Bautsch W., Klos A., and Kohl J. Guinea pig C3 specific rabbit single chain Fv antibodies from bone marrow, spleen and blood derived phage libraries. J. Immunol. Methods 236 (2000) 117-131
35. Hay E.M. Systemic lupus erythematosus. Baillieres Clin. Rheumatol. 9 (1995) 437-470
36. Hillmen P., Hall C., Marsh J.C., Elebute M., Bombara M.P., Petro B.E., Cullen M.J., Richards S.J., Rollins S.A., Mojcik C.F., and Rother R.P. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J Med. 350 (2004) 552-559
37. Hiramatsu Y., Gikakis N., Gorman III J.H., Khan M.M., Hack C.E., Velthuis H.T., Sun L., Marcinkiewicz C., Rao A.K., Niewiarowski S., Colman R.W., Edmunds Jr. L.H., and Anderson III H.L. A baboon model for hematologic studies of cardiopulmonary bypass. J. Lab. Clin. Med. 130 (1997) 412-420
38. Hughes A.E., Orr N., Esfandiary H., az-Torres M., Goodship T., and Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat. Genet. 38 (2006) 1173-1177
39. Jansen J.H., Hogasen K., and Mollnes T.E. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type-II (porcine dense deposit disease). Am. J. Pathol. 143 (1993) 1356-1365
40. Janzi M., Odling J., Pan-Hammarstrom Q., Sundberg M., Lundeberg J., Uhlen M., Hammarstrom L., and Nilsson P. Serum microarrays for large scale screening of protein levels. Mol. Cell Proteomics 4 (2005) 1942-1947
41. Johnson U., Truedsson L., and Gustavii B. Complement components in 100 newborns and their mothers determined by electroimmunoassay. APMIS 91 (1983) 147-150
42. Kavanagh D., Kemp E.J., Mayland E., Winney R.J., Duffield J.S., Warwick G., Richards A., Ward R., Goodship J.A., and Goodship T.H. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16 (2005) 2150-2155
43. Klein R.J., Zeiss C., Chew E.Y., Tsai J.Y., Sackler R.S., Haynes C., Henning A.K., Sangiovanni J.P., Mane S.M., Mayne S.T., Bracken M.B., Ferris F.L., Ott J., Barnstable C., and Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 308 (2005) 385-389
44. Kuipers S., Aerts P.C., Sjoholm A.G., Harmsen T., and Vandijk H. A hemolytic assay for the estimation of functional mannose-binding lectin levels in human serum. J. Immunol. Methods 268 (2002) 149-157
45. Kurzen H., and Brenner S. Significance of autoimmunity to non-desmoglein targets in pemphigus. Autoimmunity 39 (2006) 549-556
46. Lederer S.R., Kluth-Pepper B., Schneeberger H., Albert E., Land W., and Feucht H.E. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int. 59 (2001) 334-341
47. Link C., Hawlisch H., Vilsendorf A.M.Z., Gyleruz S., Nagel E., and Kohl J. Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation. Mol. Immunol. 36 (1999) 1235-1247
48. Liu Z., and Diaz L.A. Bullous pemphigoid: end of the century overview. J. Dermatol. 28 (2001) 647-650
49. Luzzatto L., and Gianfaldoni G. Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria. Int. J. Hematol. 84 (2006) 104-112
50. Majewski J., Schultz D.W., Weleber R.G., Schain M.B., Edwards A.O., Matise T.C., Acott T.S., Ott J., and Klein M.L. Age-related macular degeneration-a genome scan in extended families. Am. J. Hum. Genet. 73 (2003) 540-550
51. Maller J., George S., Purcell S., Fagerness J., Altshuler D., Daly M.J., and Seddon J.M. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat. Genet. 38 (2006) 1055-1059
52. Manuelian T., Hellwage J., Meri S., Caprioli J., Noris M., Heinen S., Jozsi M., Neumann H.P.H., Remuzzi G., and Zipfel P.F. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111 (2003) 1181-1190
53. Martensson U., Sjoholm A.G., Sturfelt G., Truedsson L., and Laurell A.B. Western blot analysis of human IgG reactive with the collagenous portion of C1q: evidence of distinct binding specificities. Scand. J. Immunol. 35 (1992) 735-744
54. Mastellos D., Prechl J., Laszlo G., Papp K., Olah E., Argyropoulos E., Franchini S., Tudoran R., Markiewski M., Lambris J.D., and Erdei A. Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol. Immunol. 40 (2004) 1213-1221
55. MollerKristensen M., Jensenius J.C., Jensen L., Thielens N., Rossi V., Arlaud G., and Thiel S. Levels of mannan-binding lectin-associated serine protease-2 in healthy individuals. J. Immunol. Methods 282 (2003) 159-167
56. Mollnes T.E. Early- and late-phase activation of complement evaluated by plasma levels of C3d, g and the terminal complement complex. Complement 2 (1985) 156-164
57. Mollnes T.E. Analysis of in vivo complement activation. In: Herzenberg L.A., Weir D.M., Herzenberg L., and Blackwell C. (Eds). Weir's Handbook of Experimental Immunology (1997), Blackwell Science, Boston 78.1-78.8
58. Mollnes T.E., and Harboe M. Neoepitope expression during complement activation-a model for detecting antigenic changes in proteins and activation of cascades. Immunologist 1 (1993) 43-49
59. Mollnes T.E., and Kirschfink M. Strategies of therapeutic complement inhibition. Mol. Immunol. 43 (2006) 107-121
60. Mollnes T.E., Lea T., Frøland S.S., and Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 22 (1985) 197-202
61. Mollnes T.E., Garred P., and Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin. Exp. Immunol. 73 (1988) 484-488
62. Mollnes T.E., Redl H., Hogasen K., Bengtsson A., Garred P., Speilberg L., Lea T., Oppermann M., Gotze O., and Schlag G. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin. Exp. Immunol. 91 (1993) 295-300
63. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., and Lambris J.D. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100 (2002) 1869-1877
64. Munkvad S., Jespersen J., Gram J., Overgaard K., and Ranby M. Effects of methylamine and heparin on a rapid chromogenic assay of C1-esterase inhibitor in plasma. Clin. Chem. 36 (1990) 737-741
65. Navratil J.S., Manzi S., Kao A.H., Krishnaswami S., Liu C.C., Ruffing M.J., Shaw P.S., Nilson A.C., Dryden E.R., Johnson J.J., and Ahearn J.M. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum. 54 (2006) 670-674
66. Nilsson U.R., and Nilsson B. Simplified assays of hemolytic activity of the classical and alternative complement pathways. J. Immunol. Methods 72 (1984) 49-59
67. Noris M., Brioschi S., Caprioli J., Todeschini M., Bresin E., Porrati F., Gamba S., and Remuzzi G. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362 (2003) 1542-1547
68. Notarangelo L., Casanova J.L., Fischer A., Puck J., Rosen F., Seger R., and Geha R. Primary immunodeficiency diseases: an update. J. Allergy Clin. Immunol. 114 (2004) 677-687
69. Nurnberger W., and Bhakdi S. Plasma C3d/C3 quotient as a parameter for in vivo complement activation. J. Immunol. Methods 74 (1984) 87-91
70. Odorczuk M., Keil L.B., and Debari V.A. Binding of complement component C1q to anti-beta2 glycoprotein I antibodies from patients with antiphospholipid syndrome. Inflamm. Res. 48 (1999) 524-526
71. Oppermann M., and Gotze O. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors. Immunology 82 (1994) 516-521
72. Papp K., Szekeres Z., Terenyi N., Isaak A., Erdei A., and Prechl J. On-chip complement activation adds an extra dimension to antigen microarrays. Mol. Cell Proteomics 6 (2007) 133-140
73. Pascual M., Mach-Pascual S., and Schifferli J.A. Paraproteins and complement depletion: pathogenesis and clinical syndromes. Semin. Hematol. 34 (1997) 40-48
74. Pengo V., Ruffatti A., and Iliceto S. The diagnosis of the antiphospholipid syndrome. Pathophysiol. Haemost. Thromb. 35 (2006) 175-180
75. Perez-Caballero D., Gonzalez-Rubio C., Gallardo M.E., Vera M., Lopez-Trascasa M., Rodriguez de Cordoba S., and Sanchez-Corral P. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 68 (2001) 478-484
76. Petersen S.V., Thiel S., Jensen L., Steffensen R., and Jensenius J.C. An assay for the mannan-binding lectin pathway of complement activation. J. Immunol. Methods 257 (2001) 107-116
77. Pfeifer P.H., Kawahara M.S., and Hugli T.E. Possible mechanism for in vitro complement activation in blood and plasma samples: Futhan/EDTA controls in vitro complement activation. Clin. Chem. 45 (1999) 1190-1199
78. Provost T.T., and Reichlin M. Immunopathologic studies of cutaneous lupus erythematosus. J. Clin. Immunol. 8 (1988) 223-233
79. Ramos-Casals M., Campoamor M.T., Chamorro A., Salvador G., Segura S., Botero J.C., Yague J., Cervera R., Ingelmo M., and Font J. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 13 (2004) 777-783
80. Richards A., Buddles M.R., Donne R.L., Kaplan B.S., Kirk E., Venning M.C., Tielemans C.L., Goodship J.A., and Goodship T.H. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am. J. Hum. Genet. 68 (2001) 485-490
81. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., Muslumanoglu M.H., Kavukcu S., Filler G., Pirson Y., Wen L.S., Atkinson J.P., and Goodship T.H.J. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 12966-12971
82. Richards A., Kathryn L.M., Kavanagh D., Fang C.J., Moulton E., Fremeaux-Bacchi V., Remuzzi G., Noris M., Goodship T.H., and Atkinson J.P. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol. Immunol 44 (2007) 111-122
83. Roach B., Kim Y., Jerome E., and Michael A.F. Influence of age and sex on serum complement components in children. Am. J. Dis. Child. 135 (1981) 918-920
84. Roos A., Bouwman L.H., Munoz J., Zuiverloon T., FaberKrol M.C., FallauxvandenHouten F.C., Klarmohamad N., Hack C.E., Tilanus M.G., and Daha M.R. Functional characterization of the lectin pathway of complement in human serum. Mol. Immunol. 39 (2003) 655-668
85. Salmon J.E., and Girardi G. The role of complement in the antiphospholipid syndrome. Curr. Dir. Autoimmun. 7 (2004) 133-148
86. Samano E.S., Ribeiro L.M., Gorescu R.G., Rocha K.C., and Grumach A.S. Involvement of C4 allotypes in the pathogenesis of human diseases. Rev. Hosp. Clin. Fac. Med. Sao Paulo 59 (2004) 138-144
87. Sanchez-Corral P., Gonzalez-Rubio C., Rodriguez de Cordoba S., and Lopez-Trascasa M. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol. Immunol. 41 (2004) 81-84
88. Schulze M., Baker P.J., Perkinson D.T., Johnson R.J., Ochi R.F., Stahl R.A., and Couser W.G. Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int. 35 (1989) 60-68
89. Seelen M.A., Roos A., Wieslander J., Mollnes T.E., Sjoholm A.G., Wurzner R., Loos M., Tedesco F., Sim R.B., Garred P., Alexopoulos E., Turner M.W., and Daha M.R. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Methods 296 (2005) 187-198
90. Seino J., Kinoshita Y., Sudo K., Horigome I., Sato H., Narita M., Noshiro H., Kudo K., Fukuda K., Saito T., et al. Quantitation of C4 nephritic factor by an enzyme-linked immunosorbent assay. J. Immunol. Methods 128 (1990) 101-108
91. Sjoholm A.G., Selander B., Ostenson S., Holmstrom E., and Soderstrom C. Normal human serum depleted of C1q, factor D and properdin: its use in studies of complement activation. APMIS 99 (1991) 1120-1128
92. Sjoholm A.G., Jonsson G., Braconier J.H., Sturfelt G., and Truedsson L. Complement deficiency and disease: an update. Mol. Immunol. 43 (2006) 78-85
93. Soderlind E., Strandberg L., Jirholt P., Kobayashi N., Alexeiva V., Aberg A.M., Nilsson A., Jansson B., Ohlin M., Wingren C., Danielsson L., Carlsson R., and Borrebaeck C.A. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat. Biotechnol. 18 (2000) 852-856
94. Sonntag J., Brandenburg U., Polzehl D., Strauss E., Vogel M., Dudenhausen J.W., and Obladen M. Complement system in healthy term newborns: reference values in umbilical cord blood. Pediatr. Dev. Pathol. 1 (1998) 131-135
95. Stove S., Klos A., Bautsch W., and Kohl J. Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation. J. Immunol. Methods 182 (1995) 1-5
96. Sturfelt G., and Sjoholm A.G. Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int. Arch. Allergy Appl. Immunol. 75 (1984) 75-83
97. Teisner B., Brandslund I., Grunnet N., Hansen L.K., Thellesen J., and Svehag S.E. Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation. J. Clin. Lab. Immunol. 12 (1983) 63-67
98. Thiel S., Frederiksen P.D., and Jensenius J.C. Clinical manifestations of mannan-binding lectin deficiency. Mol. Immunol. 43 (2006) 86-96
99. Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin. Immunopathol. 27 (2005) 276-285
100. Truedsson L., Sjoholm A.G., and Laurell A.B. Screening for deficiencies in the classical and alternative pathways of complement by hemolysis in gel. Acta Pathol. Microbiol. Scand. [C.] 89 (1981) 161-166
101. Turner M.W. The role of mannose-binding lectin in health and disease. Mol. Immunol. 40 (2003) 423-429
102. Vargha R., Mueller T., Arbeiter K., Regele H., Exner M., Csaicsich D., and Aufricht C. C4d in pediatric renal allograft biopsies: a marker for negative outcome in steroid-resistant rejection. Pediatr. Transplant. 10 (2006) 449-453
103. Venables J.P., Strain L., Routledge D., Bourn D., Powell H.M., Warwicker P., az-Torres M.L., Sampson A., Mead P., Webb M., Pirson Y., Jackson M.S., Hughes A., Wood K.M., Goodship J.A., and Goodship T.H. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 3 (2006) e431
104. Wagner J.L., and Hugli T.E. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. Anal. Biochem. 136 (1984) 75-88
105. Warwicker P., Goodship T.H.J., Donne R.L., Pirson Y., Nicholls A., Ward R.M., Turnpenny P., and Goodship J.A. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 53 (1998) 836-844
106. Weiler C.R., and van Dellen R.G. Genetic test indications and interpretations in patients with hereditary angioedema. Mayo Clin. Proc. 81 (2006) 958-972
107. West C.D. The complement profile in clinical medicine. Inherited and acquired conditions lowering the serum concentrations of complement component and control proteins. Complement. Inflamm. 6 (1989) 49-64
108. West C.D. Nephritic factors predispose to chronic glomerulonephritis. Am. J. Kidney Dis. 24 (1994) 956-963 [see comments]
109. Wingren C., and Borrebaeck C.A. Antibody microarrays: current status and key technological advances. OMICS 10 (2006) 411-427
110. Wouters D., Wiessenberg H.D., Hart M., Bruins P., Voskuyl A., Daha M.R., and Hack C.E. Complexes between C1q and C3 or C4: novel and specific markers for classical complement pathway activation. J. Immunol. Methods 298 (2005) 35-45
111. Yang Y., Chung E.K., Zhou B., Lhotta K., Hebert L.A., Birmingham D.J., Rovin B.H., and Yu C.Y. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr. Dir. Autoimmun. 7 (2004) 98-132
112. Zecevic R.D., Pavlovic M.D., and Stefanovic D. Lupus band test and disease activity in systemic lupus erythematosus: does it still matter?. Clin. Exp. Dermatol. 31 (2006) 358-360
113. Zipfel P.F., and Skerka C. Complement dysfunction in hemolytic uremic syndrome. Curr. Opin. Rheumatol. 18 (2006) 548-555
114. Zwirner J., Felber E., Reiter C., Riethmuller G., and Feucht H.E. Deposition of complement activation products on plastic-adsorbed immunoglobulins. A simple ELISA technique for the detection of defined complement deficiencies. J. Immunol. Methods 124 (1989) 121-129